Retrospective real-life efficacy assessment of teneligliptin in Indian T2DM patients

Nikhil Nashikkar, Vijay Panikar, Shashank Joshi, Krish Panikar, Samhita Walawalkar, Jimit Vadgama, Tejas Kamat, Khushoo Modi, Ishita Sachdev


Background: Teneligliptin is been introduced recently in Indian market and data available are limited on Indian patients. Hence, the hospital based real life retrospective evaluation was planned out to evaluate, the efficacy of teneligliptin in type 2 diabetes mellitus in Indian population. Hence study was designed, a retrospective evaluation, of efficacy of teneligliptin in type 2 diabetes mellitus in Indian population.

Methods: Data of 775 patients, who were prescribed teneligliptin was collected from hospital records. Teneligliptin 20mg was prescribed to all patients who were uncontrolled on other OHAs and for a mean duration of 8 weeks. Parameter evaluated in this study were change in FBG, PPBG and HbA1c from the baseline at 8week. With profile of outcome i.e. response and failure rates were also assessed with respect to age, gender, BMI and duration of diabetes.

Results: Of 775 patients were enrolled, 427 were males and 348 females. The average age was 53.04 years among the study population. The mean duration of diabetes was 23 months. There was significant change in HbA1c, fasting and postprandial blood glucose levels at 8 week of teneligliptin therapy. Changes in HbA1c, FPG and PPG from baseline to end of study were-1.22±1.12% (p=0.001), -35.8±25.5mg/dl (p=0.001) and -60.7±28.6mg/dl (p=0.001) respectively. Out of 775 patients, 106 (13,7%) were non-responders where it was further sub analysed with different parameter such as age, gender, BMI and duration of diabetes in order to observe response of teneligliptin in diabetic patients.

Conclusions: This real life retrospective evaluation showed efficacy of teneligliptin in real world scenario. It can be an effective alternative to conventional gliptins available for prescription in India.


BMI, Diabetes, FBG, HbA1c, PPBG, Teneligliptin

Full Text:



International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation, 2017. Available at: http://Www.Diabetesatlas.Org.

Scott LJ. Teneligliptin: A Review in type 2 diabetes. Clin Drug Invest. 2015 Nov;35(11):765-72.

American Diabetes Association. Standards of medical care in diabetes-2016. Diabetes Care. 2016;39(Suppl 1):S1-S106.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocrpract. 2016 Jan;22(1):84-113.

Goda M, Kadowaki T. Teneligliptin for the Treatment of Type 2 Diabetes. Drugs Today (BARC). 2013 Oct;49(10):615-29.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013 Nov 27;4(6):576-84.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. J Asso Physic Ind. 2003;51:1061-4.

Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (treat-INDIA study). Diabetes, metabolic syndrome and obesity: targets and therapy. 2016;9:347-53.

Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Meta Synd. 2014;6:69.

Mamza J, Mehta R, Donnelly R, Idris I. Comparative efficacy of adding sitagliptin to metformin, sulfonylurea or dual therapy: a propensity score-weighted cohort study. Diabetes therapy. 2015 Jun 1;6(2):213-26.

Hayati F, Hazim A, Sasongko TH, Hua GS, Mohamed WM, Daud J, et al. Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus. journal of Diabetes Research and Clinical Metabolism. 2014 Dec 15;3(1):10.